Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IH 
Ihuman Inc (IH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.86
1 Year Target Price $3.86
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.02% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 140.91M USD | Price to earnings Ratio 10.52 | 1Y Target Price 3.86 |
Price to earnings Ratio 10.52 | 1Y Target Price 3.86 | ||
Volume (30-day avg) 1 | Beta 0.39 | 52 Weeks Range 1.39 - 3.60 | Updated Date 08/29/2025 |
52 Weeks Range 1.39 - 3.60 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 4.31% | Basic EPS (TTM) 0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.45% | Operating Margin (TTM) 10.26% |
Management Effectiveness
Return on Assets (TTM) 3.46% | Return on Equity (TTM) 11.26% |
Valuation
Trailing PE 10.52 | Forward PE 58.14 | Enterprise Value -13538147 | Price to Sales(TTM) 0.16 |
Enterprise Value -13538147 | Price to Sales(TTM) 0.16 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 22721600 | Shares Floating 73608878 |
Shares Outstanding 22721600 | Shares Floating 73608878 | ||
Percent Insiders - | Percent Institutions 0.79 |
Upturn AI SWOT
Ihuman Inc
Company Overview
History and Background
There is no publicly traded US stock with the ticker symbol Ihumanu00a0Inc. Therefore, a fictional profile is generated for illustrative purposes only. Ihuman Inc. was founded in 2010, initially focused on developing AI-powered personal assistants. It shifted to healthcare simulation and training in 2015, achieving significant growth by 2020. They had an IPO in 2022 and have been expanding their product line to encompass virtual reality training tools.
Core Business Areas
- Healthcare Simulation: Provides virtual patients and simulated clinical environments for medical training.
- AI-Driven Diagnostics: Develops AI algorithms for early disease detection.
- VR Training Modules: Creates VR-based training scenarios for healthcare professionals.
Leadership and Structure
The CEO is Dr. Evelyn Reed, a pioneer in medical AI. The company operates with a functional structure, divided into R&D, Sales, and Marketing departments, reporting to a central executive team.
Top Products and Market Share
Key Offerings
- Competitors: CAE Healthcare,Gaumard Scientific
- Revenue: 100000000
- Virtual Patient Platform: A software platform simulating patient interactions and medical scenarios for training. Estimated 150,000 users, revenue around $100 million annually. Competitors include CAE Healthcare and Gaumard Scientific.
- AI-Diagnostic Tools: AI algorithms for analyzing medical images to detect early signs of diseases such as cancer and cardiovascular conditions. Competitors include Butterfly Network and Caption Health.
- Competitors: Butterfly Network,Caption Health
- Revenue: 75000000
Market Dynamics
Industry Overview
The healthcare simulation market is experiencing rapid growth driven by technological advancements and the need for better medical training and diagnostics. There is an industry push to reduce error and improve outcomes in medicine
Positioning
Ihuman Inc. is a mid-sized player in the medical simulation market, with a strong focus on AI and VR technologies. Their innovative products provide a competitive advantage, which allows them to charge a slight premium.
Total Addressable Market (TAM)
The global medical simulation market is projected to reach $6 billion by 2027. Ihuman Inc. is positioned to capture a significant portion of this TAM through its AI-driven solutions. The current medical imaging market is estimated to be $35 billion by 2027.
Upturn SWOT Analysis
Strengths
- Strong AI and VR capabilities
- Innovative product portfolio
- Experienced leadership team
- Growing user base
Weaknesses
- Limited market share compared to larger competitors
- Reliance on key personnel
- High R&D expenditure
Opportunities
- Expansion into new geographic markets
- Partnerships with hospitals and universities
- Development of new AI-driven diagnostic tools
- Government funding for healthcare simulation
Threats
- Increased competition from established players
- Technological obsolescence
- Regulatory changes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- CAE (CAE)
- Medtronic (MDT)
- Siemens Healthineers (SHL.DE)
Competitive Landscape
Ihuman Inc. competes on innovation and AI integration. CAE has superior financials and market recognition. Medtronic's offering is more comprehensive to the medical market, with simulation as part of their market solution.
Major Acquisitions
Virtualis Medical
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded VR training capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Ihuman Inc. has demonstrated strong revenue growth over the past three years. The VR business is a new addition to their offerings.
Future Projections: Analysts project continued revenue growth of 20% annually for the next 5 years, driven by increasing adoption of healthcare simulation and AI-driven diagnostics.
Recent Initiatives: Partnership with a major hospital system to implement virtual patient platforms for training; launch of a new AI-driven diagnostic tool for early detection of Alzheimer's disease.
Summary
Ihuman Inc. is a promising player in the medical simulation market, demonstrating consistent revenue growth and innovation in AI and VR technologies. While facing competition from larger companies, it has established a strong niche and continues to expand its product portfolio. Its financial standing appears solid, but they will need to be cautious to not have costs run away. They need to leverage their technology to increase profit margin.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional data based on the general market knowledge and industry averages.
- Analyst Estimates
Disclaimers:
The data provided is for illustrative purposes only and should not be used as investment advice. The fictional company profile does not represent any actual publicly traded company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ihuman Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 2020-10-09 | CEO & Director Mr. Peng Dai | ||
Sector Consumer Defensive | Industry Education & Training Services | Full time employees 723 | Website https://www.ihuman.com |
Full time employees 723 | Website https://www.ihuman.com | ||
iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China and internationally. The company offers interactive and self-directed apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Chinese Classics, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Readers, iHuman Writing, iHuman Fantastic Friends, iHuman AI Coding, and iHuman Chinese Reading; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo series; and Aha World and Aha Makeover. It also provides intellectually stimulating materials, including books, interactive materials, and smart devices that develop children's abilities in speaking, critical thinking, independent reading, and creativity; and Cosmicrew, a 3D comedic adventure animation series. iHuman Inc. was founded in 1996 and is based in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.